In vitro activity of ceftobiprole against frequently encountered aerobic and facultative Gram-positive and Gram-negative bacterial pathogens: results of the CANWARD 2007–2009 study

The in vitro activity of ceftobiprole was evaluated against 15 011 clinical isolates obtained from patients in Canadian hospitals between 2007 and 2009. All Staphylococcus aureus were susceptible to ceftobiprole (MIC90′s for methicillin-susceptible Staphylococcus aureus and methicillin-resistant Staphylococcus aureus of ≤1 μg/mL and 2 μg/mL, respectively). Ceftobiprole was active against penicillin-susceptible Streptococcus pneumoniae (MIC90, ≤0.06 μg/mL), penicillin-resistant Streptococcus pneumoniae (MIC90, 0.5 μg/mL), Streptococcus pyogenes (MIC90, ≤0.06 μg/mL), Staphylococcus epidermidis (MIC90, ≤1 μg/mL), and Enterococcus faecalis (MIC90, ≤1 μg/mL). Over 90% of Escherichia coli, Klebsiella pneumoniae, Enterobacter aerogenes, Citrobacter freundii, Proteus mirabilis, and Serratia marcescens isolates were inhibited by a ceftobiprole concentration of ≤1 μg/mL. Ceftobiprole was not active against extended-spectrum β-lactamase–producing Escherichia coli and K. pneumoniae. The in vitro activity of ceftobiprole versus Pseudomonas aeruginosa was similar to that of cefepime (MIC90, 16 μg/mL). The broad spectrum of activity by ceftobiprole would support further study of this agent in the treatment of hospital-acquired infections.